4.7 Article

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

期刊

BLOOD
卷 119, 期 19, 页码 4467-4475

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-11-393694

关键词

-

资金

  1. ENosAI [09SYN-13-880]
  2. European Union
  3. Hellenic General Secretariat for Research and Technology
  4. Cariplo Foundation, Milan, Italy
  5. Program Molecular Clinical Oncology-5 per mille [9965]
  6. Associazione Italiana per la Ricerca sul Cancro (AIRC), Milano, Italy
  7. National Cancer Institute/National Institutes of Health [RO1 CA81554]
  8. Nordic Cancer Union
  9. Swedish Cancer Society
  10. Swedish Research Council
  11. Uppsala University Hospital
  12. Lion's Cancer Research Foundations in Uppsala
  13. Ministry of Health of the Czech Republic [MZ CZ NS10439-3/2009]
  14. A. G. Leventis Foundation

向作者/读者索取更多资源

Mounting evidence indicates that grouping of chronic lymphocytic leukemia (CLL) into distinct subsets with stereotyped BCRs is functionally and prognostically relevant. However, several issues need revisiting, including the criteria for identification of BCR stereotypy and its actual frequency as well as the identification of CLL-biased features in BCR Ig stereotypes. To this end, we examined 7596 Ig VH (IGHV-IGHD-IGHJ) sequences from 7424 CLL patients, 3 times the size of the largest published series, with an updated version of our purpose-built clustering algorithm. We document that CLL may be subdivided into 2 distinct categories: one with stereotyped and the other with nonstereotyped BCRs, at an approximate ratio of 1: 2, and provide evidence suggesting a different ontogeny for these 2 categories. We also show that subset-defining sequence patterns in CLL differ from those underlying BCR stereotypy in other B-cell malignancies. Notably, 19 major subsets contained from 20 to 213 sequences each, collectively accounting for 943 sequences or one-eighth of the cohort. Hence, this compartmentalized examination of VH sequences may pave the way toward a molecular classification of CLL with implications for targeted therapeutic interventions, applicable to a significant number of patients assigned to the same subset. (Blood. 2012;119(19):4467-4475)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据